<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00072436</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00038</org_study_id>
    <secondary_id>6051</secondary_id>
    <secondary_id>P30CA006516</secondary_id>
    <secondary_id>U01CA062490</secondary_id>
    <secondary_id>CDR0000339727</secondary_id>
    <nct_id>NCT00072436</nct_id>
  </id_info>
  <brief_title>Gemcitabine Hydrochloride and Alvocidib in Treating Patients With Solid Tumors</brief_title>
  <official_title>A Phase I Trial of Gemcitabine Followed by a Short Infusion of Flavopiridol in Patients With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial is studying the side effects and best dose of gemcitabine hydrochloride&#xD;
      and alvocidib in treating patients with solid tumors. Drugs used in chemotherapy, such as&#xD;
      gemcitabine hydrochloride and alvocidib, use different ways to stop tumor cells from dividing&#xD;
      so they stop growing or die. Combining more than one drug may kill more tumor cells&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of gemcitabine and flavopiridol in patients with&#xD;
      solid tumors.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the safety profile and toxic effects of this regimen in these patients.&#xD;
&#xD;
      II. Determine the pharmacokinetics of flavopiridol with and without gemcitabine in these&#xD;
      patients.&#xD;
&#xD;
      III. Determine, using pharmacodynamic assays, the activity of flavopiridol as a cdk inhibitor&#xD;
      in these patients.&#xD;
&#xD;
      IV. Determine, using pharmacodynamic assays, the markers of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study.&#xD;
&#xD;
      Some patients receive an initial dose of alvocidib IV over 1-7 hours on day 1 (course 0).&#xD;
      Beginning 1 week later and for all subsequent courses, all patients receive gemcitabine&#xD;
      hydrochloride IV over 60-150 minutes on days 1 and 15 and alvocidib IV over 1-7 hours on days&#xD;
      2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of gemcitabine hydrochloride and alvocidib&#xD;
      until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose&#xD;
      preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the&#xD;
      MTD is determined, up to 10 additional patients receive treatment at that dose.&#xD;
&#xD;
      Patients are followed at 30 days after study completion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose-limiting toxicity (DLT) graded by National Cancer Institute (NCI) Common Toxicity Criteria</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose, defined as one dose level below the dose that induces DLT in more than 1/6 patients</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Some patients receive an initial dose of alvocidib IV over 1-7 hours on day 1 (course 0). Beginning 1 week later and for all subsequent courses, all patients receive gemcitabine hydrochloride IV over 60-150 minutes on days 1 and 15 and alvocidib IV over 1-7 hours on days 2 and 16. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
Cohorts of 3-6 patients receive escalating doses of gemcitabine hydrochloride and alvocidib until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, up to 10 additional patients receive treatment at that dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>difluorodeoxycytidine hydrochloride</other_name>
    <other_name>gemcitabine</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alvocidib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>FLAVO</other_name>
    <other_name>flavopiridol</other_name>
    <other_name>HMR 1275</other_name>
    <other_name>L-868275</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active infection&#xD;
&#xD;
          -  No severe malnutrition&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens:&#xD;
&#xD;
               -  Prior combined modality therapy (e.g., full-dose chemotherapy with&#xD;
                  radiosensitizing chemotherapy and radiotherapy) is considered 1 prior regimen if&#xD;
                  all therapy was delivered as part of 1 comprehensive treatment plan&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
          -  At least 6 months since prior radiotherapy to the lung parenchyma or mediastinum and&#xD;
             no evidence of radiation pneumonitis on chest CT scan&#xD;
&#xD;
          -  At least 4 weeks since other prior radiotherapy and recovered&#xD;
&#xD;
          -  No prior radiotherapy to more than 50% of marrow volume&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  Histologically confirmed solid tumor for which gemcitabine is a treatment option OR&#xD;
             for which no efficacious therapy exists&#xD;
&#xD;
          -  Must meet criteria for 1 of the following:&#xD;
&#xD;
               -  Measurable disease:&#xD;
&#xD;
                    -  At least 1 unidimensionally measurable lesion at least 20 mm by conventional&#xD;
                       techniques OR at least 10 mm by spiral CT scan&#xD;
&#xD;
               -  Nonmeasurable disease, including any of the following:&#xD;
&#xD;
                    -  Small lesions (less than 20 mm by conventional techniques OR less than 10 mm&#xD;
                       by spiral CT scan)&#xD;
&#xD;
                    -  Bone lesions&#xD;
&#xD;
                    -  Cytologically positive pleural or peritoneal disease&#xD;
&#xD;
                    -  Elevated tumor markers (e.g., carcinoembryonic antigen, CA 125, CA 19-9, or&#xD;
                       other tumor marker)&#xD;
&#xD;
                    -  Multinodular or confluent nonmeasurable pulmonary, hepatic, adrenal,&#xD;
                       intra-abdominal, or skin metastases&#xD;
&#xD;
                    -  No active CNS metastases&#xD;
&#xD;
                    -  Previously treated CNS metastases must be stable with no symptoms for 4&#xD;
                       weeks after completion of treatment AND patient must be off steroid therapy&#xD;
                       or on a stable dose for at least the past 2 weeks&#xD;
&#xD;
                    -  No known leptomeningeal metastases&#xD;
&#xD;
          -  Performance status:&#xD;
&#xD;
               -  ECOG 0-1&#xD;
&#xD;
          -  Hematopoietic:&#xD;
&#xD;
               -  Absolute neutrophil count at least 1,500/mm3;&#xD;
&#xD;
               -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Hepatic:&#xD;
&#xD;
               -  Bilirubin no greater than 1.5 mg/dL;&#xD;
&#xD;
               -  SGOT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
          -  Renal:&#xD;
&#xD;
               -  Creatinine no greater than 1.5 mg/dL OR&#xD;
&#xD;
               -  Creatinine clearance at least 50 mL/min&#xD;
&#xD;
          -  Cardiovascular:&#xD;
&#xD;
               -  None of the following within the past 6 months:&#xD;
&#xD;
                    -  Myocardial infarction;&#xD;
&#xD;
                    -  Unstable angina;&#xD;
&#xD;
                    -  Transient ischemic attack;&#xD;
&#xD;
                    -  Cerebrovascular accident&#xD;
&#xD;
                         -  No new cardiac arrhythmia possibly related to cardiac ischemia;&#xD;
&#xD;
                         -  No large and potentially symptomatic pericardial effusion;&#xD;
&#xD;
                         -  No cardiac disease that would preclude study participation&#xD;
&#xD;
          -  Pulmonary:&#xD;
&#xD;
               -  No pulmonary embolism within the past 6 months;&#xD;
&#xD;
               -  No large and potentially symptomatic pleural effusion;&#xD;
&#xD;
               -  No pulmonary disease that would preclude study participation&#xD;
&#xD;
          -  Gastrointestinal:&#xD;
&#xD;
               -  No intractable emesis;&#xD;
&#xD;
               -  No grade 2 or greater chronic diarrheal disease within the past 6 months&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Geoffrey Shapiro</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital Cancer Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>November 4, 2003</study_first_submitted>
  <study_first_submitted_qc>November 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2003</study_first_posted>
  <last_update_submitted>July 1, 2013</last_update_submitted>
  <last_update_submitted_qc>July 1, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Alvocidib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

